APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tuberculosis Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Tuberculosis Vaccines Market Outlook and Growth Opportunities 2026

20 December 2025196 pages

Choose your research edition.

Industry ResearchTuberculosis Vaccines Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Tuberculosis Vaccines Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Tuberculosis Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tuberculosis Vaccines Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Tuberculosis Vaccines Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Tuberculosis Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Tuberculosis Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Tuberculosis Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tuberculosis Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Tuberculosis Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Tuberculosis Vaccines market include Bavarian Nordic, China National Biotec Group, GreenSignal Bio Pharma, IDT Biologics, Japan BCG Lab, Serum Institute of India, Taj Pharmaceuticals, GlaxoSmithKline and Merck, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Tuberculosis Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tuberculosis Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tuberculosis Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Tuberculosis Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Tuberculosis Vaccines Segment by Company

Bavarian Nordic

China National Biotec Group

GreenSignal Bio Pharma

IDT Biologics

Japan BCG Lab

Serum Institute of India

Taj Pharmaceuticals

GlaxoSmithKline

Merck

Sanofi

Tuberculosis Vaccines Segment by Type

Immunotherapeutic Vaccines

Booster Vaccines

Others

Tuberculosis Vaccines Segment by Application

Hospitals

Clinics

Others

Tuberculosis Vaccines Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Tuberculosis Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Tuberculosis Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Tuberculosis Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze Tuberculosis Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tuberculosis Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tuberculosis Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tuberculosis Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Tuberculosis Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Tuberculosis Vaccines industry.

Chapter 3: Detailed analysis of Tuberculosis Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Tuberculosis Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Tuberculosis Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Tuberculosis Vaccines Industry Trends Table 2. Tuberculosis Vaccines Industry Drivers Table 3. Tuberculosis Vaccines Industry Opportunities and Challenges Table 4. Tuberculosis Vaccines Industry Restraints Table 5. Global Tuberculosis Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Tuberculosis Vaccines Revenue Share by Company (2021-2026) Table 7. Global Tuberculosis Vaccines Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Tuberculosis Vaccines Sales Volume Share by Company (2021-2026) Table 9. Global Tuberculosis Vaccines Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Tuberculosis Vaccines Company Ranking, (2024-2026) & (USD Million) Table 11. Global Tuberculosis Vaccines Key Company Manufacturing Base & Headquarters Table 12. Global Tuberculosis Vaccines Company, Product Type & Application Table 13. Global Tuberculosis Vaccines Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Tuberculosis Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Immunotherapeutic Vaccines Table 18. Significant Companies of Booster Vaccines Table 19. Significant Companies of Others Table 20. Global Tuberculosis Vaccines Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 21. Global Tuberculosis Vaccines Sales Volume by Type (2021-2026) & (W Units) Table 22. Global Tuberculosis Vaccines Sales Volume by Type (2027-2032) & (W Units) Table 23. Global Tuberculosis Vaccines Sales Volume Share by Type (2021-2026) Table 24. Global Tuberculosis Vaccines Sales Volume Share by Type (2027-2032) Table 25. Global Tuberculosis Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Tuberculosis Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Tuberculosis Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Tuberculosis Vaccines Sales Value Share by Type (2021-2026) Table 29. Global Tuberculosis Vaccines Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospitals Table 31. Significant Companies of Clinics Table 32. Significant Companies of Others Table 33. Global Tuberculosis Vaccines Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 34. Global Tuberculosis Vaccines Sales Volume by Application (2021-2026) & (W Units) Table 35. Global Tuberculosis Vaccines Sales Volume by Application (2027-2032) & (W Units) Table 36. Global Tuberculosis Vaccines Sales Volume Share by Application (2021-2026) Table 37. Global Tuberculosis Vaccines Sales Volume Share by Application (2027-2032) Table 38. Global Tuberculosis Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Tuberculosis Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Tuberculosis Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Tuberculosis Vaccines Sales Value Share by Application (2021-2026) Table 42. Global Tuberculosis Vaccines Sales Value Share by Application (2027-2032) Table 43. Global Tuberculosis Vaccines Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 44. Global Tuberculosis Vaccines Sales by Region (2021-2026) & (W Units) Table 45. Global Tuberculosis Vaccines Sales Market Share by Region (2021-2026) Table 46. Global Tuberculosis Vaccines Sales by Region (2027-2032) & (W Units) Table 47. Global Tuberculosis Vaccines Sales Market Share by Region (2027-2032) Table 48. Global Tuberculosis Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Tuberculosis Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Tuberculosis Vaccines Sales Value Share by Region (2021-2026) Table 51. Global Tuberculosis Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Tuberculosis Vaccines Sales Value Share by Region (2027-2032) Table 53. Global Tuberculosis Vaccines Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Tuberculosis Vaccines Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Tuberculosis Vaccines Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 56. Global Tuberculosis Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Tuberculosis Vaccines Sales by Country (2021-2026) & (W Units) Table 58. Global Tuberculosis Vaccines Sales Market Share by Country (2021-2026) Table 59. Global Tuberculosis Vaccines Sales by Country (2027-2032) & (W Units) Table 60. Global Tuberculosis Vaccines Sales Market Share by Country (2027-2032) Table 61. Global Tuberculosis Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Tuberculosis Vaccines Sales Value Market Share by Country (2021-2026) Table 63. Global Tuberculosis Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Tuberculosis Vaccines Sales Value Market Share by Country (2027-2032) Table 65. Bavarian Nordic Company Information Table 66. Bavarian Nordic Business Overview Table 67. Bavarian Nordic Tuberculosis Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Bavarian Nordic Tuberculosis Vaccines Product Portfolio Table 69. Bavarian Nordic Recent Development Table 70. China National Biotec Group Company Information Table 71. China National Biotec Group Business Overview Table 72. China National Biotec Group Tuberculosis Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. China National Biotec Group Tuberculosis Vaccines Product Portfolio Table 74. China National Biotec Group Recent Development Table 75. GreenSignal Bio Pharma Company Information Table 76. GreenSignal Bio Pharma Business Overview Table 77. GreenSignal Bio Pharma Tuberculosis Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. GreenSignal Bio Pharma Tuberculosis Vaccines Product Portfolio Table 79. GreenSignal Bio Pharma Recent Development Table 80. IDT Biologics Company Information Table 81. IDT Biologics Business Overview Table 82. IDT Biologics Tuberculosis Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. IDT Biologics Tuberculosis Vaccines Product Portfolio Table 84. IDT Biologics Recent Development Table 85. Japan BCG Lab Company Information Table 86. Japan BCG Lab Business Overview Table 87. Japan BCG Lab Tuberculosis Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Japan BCG Lab Tuberculosis Vaccines Product Portfolio Table 89. Japan BCG Lab Recent Development Table 90. Serum Institute of India Company Information Table 91. Serum Institute of India Business Overview Table 92. Serum Institute of India Tuberculosis Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Serum Institute of India Tuberculosis Vaccines Product Portfolio Table 94. Serum Institute of India Recent Development Table 95. Taj Pharmaceuticals Company Information Table 96. Taj Pharmaceuticals Business Overview Table 97. Taj Pharmaceuticals Tuberculosis Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Taj Pharmaceuticals Tuberculosis Vaccines Product Portfolio Table 99. Taj Pharmaceuticals Recent Development Table 100. GlaxoSmithKline Company Information Table 101. GlaxoSmithKline Business Overview Table 102. GlaxoSmithKline Tuberculosis Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. GlaxoSmithKline Tuberculosis Vaccines Product Portfolio Table 104. GlaxoSmithKline Recent Development Table 105. Merck Company Information Table 106. Merck Business Overview Table 107. Merck Tuberculosis Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Merck Tuberculosis Vaccines Product Portfolio Table 109. Merck Recent Development Table 110. Sanofi Company Information Table 111. Sanofi Business Overview Table 112. Sanofi Tuberculosis Vaccines Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Sanofi Tuberculosis Vaccines Product Portfolio Table 114. Sanofi Recent Development Table 115. Key Raw Materials Table 116. Raw Materials Key Suppliers Table 117. Tuberculosis Vaccines Distributors List Table 118. Tuberculosis Vaccines Customers List Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Tuberculosis Vaccines Product Image Figure 2. Global Tuberculosis Vaccines Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tuberculosis Vaccines Sales Value (2021-2032) & (US$ Million) Figure 4. Global Tuberculosis Vaccines Sales (2021-2032) & (W Units) Figure 5. Global Tuberculosis Vaccines Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Tuberculosis Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Immunotherapeutic Vaccines Image Figure 10. Booster Vaccines Image Figure 11. Others Image Figure 12. Global Tuberculosis Vaccines Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 13. Global Tuberculosis Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Tuberculosis Vaccines Sales Volume Share by Type (2021-2032) Figure 15. Global Tuberculosis Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Tuberculosis Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Tuberculosis Vaccines Sales Value Share by Type (2021-2032) Figure 18. Hospitals Image Figure 19. Clinics Image Figure 20. Others Image Figure 21. Global Tuberculosis Vaccines Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 22. Global Tuberculosis Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Tuberculosis Vaccines Sales Volume Share by Application (2021-2032) Figure 24. Global Tuberculosis Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Tuberculosis Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Tuberculosis Vaccines Sales Value Share by Application (2021-2032) Figure 27. Global Tuberculosis Vaccines Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 28. Global Tuberculosis Vaccines Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Tuberculosis Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Tuberculosis Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Tuberculosis Vaccines Sales Value (2021-2032) & (US$ Million) Figure 32. North America Tuberculosis Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Tuberculosis Vaccines Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Tuberculosis Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Tuberculosis Vaccines Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Tuberculosis Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Tuberculosis Vaccines Sales Value (2021-2032) & (US$ Million) Figure 38. South America Tuberculosis Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Tuberculosis Vaccines Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Tuberculosis Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Tuberculosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Tuberculosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Tuberculosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Tuberculosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Tuberculosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Tuberculosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Tuberculosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Tuberculosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Tuberculosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Tuberculosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Tuberculosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Tuberculosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Tuberculosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Tuberculosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Tuberculosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Tuberculosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Tuberculosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Tuberculosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Tuberculosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Tuberculosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Tuberculosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Tuberculosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Tuberculosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Tuberculosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Tuberculosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Tuberculosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Tuberculosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Tuberculosis Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Tuberculosis Vaccines Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Tuberculosis Vaccines Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Immunotherapeutic Vaccines
  • Booster Vaccines
  • Others
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Bavarian Nordic
  • China National Biotec Group
  • GreenSignal Bio Pharma
  • IDT Biologics
  • Japan BCG Lab
  • Serum Institute of India
  • Taj Pharmaceuticals
  • GlaxoSmithKline
  • Merck
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Tuberculosis Vaccines Sales Value (2021-2032)
  4. 1.2.2 Global Tuberculosis Vaccines Sales Volume (2021-2032)
  5. 1.2.3 Global Tuberculosis Vaccines Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Tuberculosis Vaccines Market Dynamics
  1. 2.1 Tuberculosis Vaccines Industry Trends
  2. 2.2 Tuberculosis Vaccines Industry Drivers
  3. 2.3 Tuberculosis Vaccines Industry Opportunities and Challenges
  4. 2.4 Tuberculosis Vaccines Industry Restraints
3 Tuberculosis Vaccines Market by Company
  1. 3.1 Global Tuberculosis Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global Tuberculosis Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global Tuberculosis Vaccines Sales Volume by Company (2021-2026)
  4. 3.4 Global Tuberculosis Vaccines Average Price by Company (2021-2026)
  5. 3.5 Global Tuberculosis Vaccines Company Ranking (2024-2026)
  6. 3.6 Global Tuberculosis Vaccines Company Manufacturing Base and Headquarters
  7. 3.7 Global Tuberculosis Vaccines Company Product Type and Application
  8. 3.8 Global Tuberculosis Vaccines Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Tuberculosis Vaccines Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Tuberculosis Vaccines Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Tuberculosis Vaccines Market by Type
  1. 4.1 Tuberculosis Vaccines Type Introduction
  2. 4.1.1 Immunotherapeutic Vaccines
  3. 4.1.2 Booster Vaccines
  4. 4.1.3 Others
  5. 4.2 Global Tuberculosis Vaccines Sales Volume by Type
  6. 4.2.1 Global Tuberculosis Vaccines Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Tuberculosis Vaccines Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Tuberculosis Vaccines Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Tuberculosis Vaccines Sales Value by Type
  10. 4.3.1 Global Tuberculosis Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Tuberculosis Vaccines Sales Value by Type (2021-2032)
  12. 4.3.3 Global Tuberculosis Vaccines Sales Value Share by Type (2021-2032)
5 Tuberculosis Vaccines Market by Application
  1. 5.1 Tuberculosis Vaccines Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Tuberculosis Vaccines Sales Volume by Application
  6. 5.2.1 Global Tuberculosis Vaccines Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Tuberculosis Vaccines Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Tuberculosis Vaccines Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Tuberculosis Vaccines Sales Value by Application
  10. 5.3.1 Global Tuberculosis Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Tuberculosis Vaccines Sales Value by Application (2021-2032)
  12. 5.3.3 Global Tuberculosis Vaccines Sales Value Share by Application (2021-2032)
6 Tuberculosis Vaccines Regional Sales and Value Analysis
  1. 6.1 Global Tuberculosis Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Tuberculosis Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Tuberculosis Vaccines Sales by Region: 2021-2026
  4. 6.2.2 Global Tuberculosis Vaccines Sales by Region (2027-2032)
  5. 6.3 Global Tuberculosis Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Tuberculosis Vaccines Sales Value by Region (2021-2032)
  7. 6.4.1 Global Tuberculosis Vaccines Sales Value by Region: 2021-2026
  8. 6.4.2 Global Tuberculosis Vaccines Sales Value by Region (2027-2032)
  9. 6.5 Global Tuberculosis Vaccines Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Tuberculosis Vaccines Sales Value (2021-2032)
  12. 6.6.2 North America Tuberculosis Vaccines Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Tuberculosis Vaccines Sales Value (2021-2032)
  15. 6.7.2 Europe Tuberculosis Vaccines Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Tuberculosis Vaccines Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Tuberculosis Vaccines Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Tuberculosis Vaccines Sales Value (2021-2032)
  21. 6.9.2 South America Tuberculosis Vaccines Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Tuberculosis Vaccines Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Tuberculosis Vaccines Sales Value Share by Country, 2025 VS 2032
7 Tuberculosis Vaccines Country-level Sales and Value Analysis
  1. 7.1 Global Tuberculosis Vaccines Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Tuberculosis Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Tuberculosis Vaccines Sales by Country (2021-2032)
  4. 7.3.1 Global Tuberculosis Vaccines Sales by Country (2021-2026)
  5. 7.3.2 Global Tuberculosis Vaccines Sales by Country (2027-2032)
  6. 7.4 Global Tuberculosis Vaccines Sales Value by Country (2021-2032)
  7. 7.4.1 Global Tuberculosis Vaccines Sales Value by Country (2021-2026)
  8. 7.4.2 Global Tuberculosis Vaccines Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Tuberculosis Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Tuberculosis Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Tuberculosis Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Tuberculosis Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Tuberculosis Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Tuberculosis Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Tuberculosis Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Tuberculosis Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Tuberculosis Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Tuberculosis Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Tuberculosis Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Tuberculosis Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Tuberculosis Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Tuberculosis Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Tuberculosis Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Tuberculosis Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Tuberculosis Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Tuberculosis Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Tuberculosis Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Tuberculosis Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Tuberculosis Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Tuberculosis Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Tuberculosis Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Tuberculosis Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Tuberculosis Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Tuberculosis Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Tuberculosis Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Tuberculosis Vaccines Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Tuberculosis Vaccines Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Tuberculosis Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bavarian Nordic
  2. 8.1.1 Bavarian Nordic Company Information
  3. 8.1.2 Bavarian Nordic Business Overview
  4. 8.1.3 Bavarian Nordic Tuberculosis Vaccines Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bavarian Nordic Tuberculosis Vaccines Product Portfolio
  6. 8.1.5 Bavarian Nordic Recent Developments
  7. 8.2 China National Biotec Group
  8. 8.2.1 China National Biotec Group Company Information
  9. 8.2.2 China National Biotec Group Business Overview
  10. 8.2.3 China National Biotec Group Tuberculosis Vaccines Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 China National Biotec Group Tuberculosis Vaccines Product Portfolio
  12. 8.2.5 China National Biotec Group Recent Developments
  13. 8.3 GreenSignal Bio Pharma
  14. 8.3.1 GreenSignal Bio Pharma Company Information
  15. 8.3.2 GreenSignal Bio Pharma Business Overview
  16. 8.3.3 GreenSignal Bio Pharma Tuberculosis Vaccines Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 GreenSignal Bio Pharma Tuberculosis Vaccines Product Portfolio
  18. 8.3.5 GreenSignal Bio Pharma Recent Developments
  19. 8.4 IDT Biologics
  20. 8.4.1 IDT Biologics Company Information
  21. 8.4.2 IDT Biologics Business Overview
  22. 8.4.3 IDT Biologics Tuberculosis Vaccines Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 IDT Biologics Tuberculosis Vaccines Product Portfolio
  24. 8.4.5 IDT Biologics Recent Developments
  25. 8.5 Japan BCG Lab
  26. 8.5.1 Japan BCG Lab Company Information
  27. 8.5.2 Japan BCG Lab Business Overview
  28. 8.5.3 Japan BCG Lab Tuberculosis Vaccines Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Japan BCG Lab Tuberculosis Vaccines Product Portfolio
  30. 8.5.5 Japan BCG Lab Recent Developments
  31. 8.6 Serum Institute of India
  32. 8.6.1 Serum Institute of India Company Information
  33. 8.6.2 Serum Institute of India Business Overview
  34. 8.6.3 Serum Institute of India Tuberculosis Vaccines Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Serum Institute of India Tuberculosis Vaccines Product Portfolio
  36. 8.6.5 Serum Institute of India Recent Developments
  37. 8.7 Taj Pharmaceuticals
  38. 8.7.1 Taj Pharmaceuticals Company Information
  39. 8.7.2 Taj Pharmaceuticals Business Overview
  40. 8.7.3 Taj Pharmaceuticals Tuberculosis Vaccines Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Taj Pharmaceuticals Tuberculosis Vaccines Product Portfolio
  42. 8.7.5 Taj Pharmaceuticals Recent Developments
  43. 8.8 GlaxoSmithKline
  44. 8.8.1 GlaxoSmithKline Company Information
  45. 8.8.2 GlaxoSmithKline Business Overview
  46. 8.8.3 GlaxoSmithKline Tuberculosis Vaccines Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 GlaxoSmithKline Tuberculosis Vaccines Product Portfolio
  48. 8.8.5 GlaxoSmithKline Recent Developments
  49. 8.9 Merck
  50. 8.9.1 Merck Company Information
  51. 8.9.2 Merck Business Overview
  52. 8.9.3 Merck Tuberculosis Vaccines Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Merck Tuberculosis Vaccines Product Portfolio
  54. 8.9.5 Merck Recent Developments
  55. 8.10 Sanofi
  56. 8.10.1 Sanofi Company Information
  57. 8.10.2 Sanofi Business Overview
  58. 8.10.3 Sanofi Tuberculosis Vaccines Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Sanofi Tuberculosis Vaccines Product Portfolio
  60. 8.10.5 Sanofi Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Tuberculosis Vaccines Value Chain Analysis
  2. 9.1.1 Tuberculosis Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Tuberculosis Vaccines Sales Mode & Process
  6. 9.2 Tuberculosis Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Tuberculosis Vaccines Distributors
  9. 9.2.3 Tuberculosis Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst